Randomized Trial of Vaccines for Zaire Ebola Virus Disease.
null nullMark KiehLaura RichertAbdoul H BeavoguiBirgit GrundBailah LeighEric D'OrtenzioSeydou DoumbiaEdouard LhommeSamba SowRenaud VatrinetCéline RoyStephen B KennedySylvain FayeShelley LeesNiouma P MillimounoAlseny M CamaraMohamed SamaiGibrilla F DeenMoussa DoumbiaHélène EspérouJerome PiersonDeborah Watson-JonesAlpha DialloDeborah WentworthChelsea McLeanJakub SimonAurélie WiedemannBonnie Dighero-KempLisa HensleyHenry Clifford LaneYves LevyPeter PiotBrian GreenwoodGeneviève ChêneJames NeatonYazdan YazdanpanahPublished in: The New England journal of medicine (2022)
No safety concerns were identified in this trial. With all three vaccine regimens, immune responses were seen from day 14 through month 12. (Funded by the National Institutes of Health and others; PREVAC ClinicalTrials.gov number, NCT02876328; EudraCT numbers, 2017-001798-18 and 2017-001798-18/3rd; and Pan African Clinical Trials Registry number, PACTR201712002760250.).